Related Experiment Video

Updated: Jul 10, 2026

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Interferon-alpha enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis

Xiang-wei Yuan1, Xiao-feng Zhu, Xiu-fang Huang

  • 1Department of Orthopedic Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.

Acta Pharmacologica Sinica
|October 26, 2007
PubMed
Abstract

Insights

Interferon-alpha (IFNalpha) boosts doxorubicin effectiveness in osteosarcoma cells by inducing p53-dependent apoptosis. This combination therapy shows promise for treating osteosarcoma with functional p53.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Osteosarcoma is a primary bone cancer with limited treatment options.
  • Doxorubicin is a standard chemotherapeutic agent, but resistance can develop.
  • Interferon-alpha (IFNalpha) has shown potential anti-cancer properties.

Purpose of the Study:

  • To investigate if IFNalpha can enhance doxorubicin sensitivity in osteosarcoma cells.
  • To elucidate the molecular mechanisms underlying this potential enhancement.
  • To assess the role of the p53 pathway in IFNalpha and doxorubicin interaction.

Main Methods:

  • Cell viability was assessed using MTT assays.
  • Apoptosis was evaluated through flow cytometry, Hoechst staining, DNA fragmentation, and caspase activation.
  • Protein expression and p53 dependence were analyzed using Western blotting and siRNA transfection.

Main Results:

  • IFNalpha significantly increased doxorubicin-induced apoptosis in p53-wild osteosarcoma cells (U2OS), but not in p53-mutant cells (MG63).
  • IFNalpha upregulated p53, Bax, Mdm2, and p21, while downregulating Bcl-2, and activating caspase-3 and PARP cleavage in U2OS cells.
  • Silencing p53 with siRNA diminished the combined efficacy of IFNalpha and doxorubicin.

Conclusions:

  • IFNalpha enhances doxorubicin sensitivity in osteosarcoma cells via a p53-dependent apoptotic pathway.
  • Combining IFNalpha with conventional chemotherapy may represent a viable strategy for treating osteosarcoma patients with functional p53.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...